Evidence map›Paper›PMID 41117719›Full record

ArticleFuture microbiology2025

In vitro and in vivo activity of Melittin combined with imipenem and meropenem against carbapenem-resistant

Demet Genç Karadenİz, Banu Kaskatepe, Şükran Öztürk, Meryem Güvenİr

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Future microbiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Melittin-Loaded FeInternational journal of nanomedicine · 2026
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Demet Genç KaradenİzInstitute of Health Sciences, Ankara University, Ankara, Türkiye.
Banu KaskatepeDepartment of Pharmaceutical Microbiology, Faculty of Pharmacy, Ankara University, Ankara, Türkiye.
Şükran ÖztürkDepartment of Pharmaceutical Microbiology, Zonguldak Bülent Ecevit University, Zonguldak, Türkiye.
Meryem GüvenİrDepartment of Medical Microbiology, Faculty of Medicine, Cyprus Health and Social Sciences University, Güzelyurt, Türkiye.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectivesTo investigate the antimicrobial efficacy of Melittin (MEL) against carbapenem-resistant MATERIALS AND

methodsMinimum Inhibitory Concentrations (MICs) of MEL, imipenem (IMP), and meropenem (MER) were evaluated through the microdilution method in 10 resistant isolates. Synergistic interactions were assessed using checkerboard, time-kill assays, and an in vivo

resultsMEL MICs ranged from 31.25-62.5 mg/L. Only the M5 isolate showed synergy with both combinations. Fractional Inhibitory Concentration Index (FICI) values were 0.375 for MEL+MER and 0.5 for MEL+IMP. Larvae treated with MEL combinations had increased survival rates compared to the infection group.

conclusionsMEL appears to be a promising therapeutic candidate against carbapenem-resistant

Indexed as

Acinetobacter baumanniiAcinetobacter InfectionsAnti-Bacterial AgentsImipenemMelittenMeropenemAnimalsCarbapenemsDisease Models, AnimalDrug SynergismHumansLarvaMicrobial Sensitivity TestsAnti-Bacterial AgentsCarbapenemsImipenemMelittenMeropenemAcinetobacter baumanniiantimicrobial resistanceGalleria mellonellaMelittintime kill assay

Identifiers

PMID41117719
PMCPMC12667626

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.